ProCE Banner Activity

How I Currently Use PARP Inhibitors to Improve Patient Outcomes in Breast Cancer

Clinical Thought
Curious about what the latest with PARP inhibition in breast cancer? Read this commentary to gain expert perspectives on optimal current and future clinical use of PARP inhibitors in early, metastatic, and triple-negative breast cancer.

Released: September 22, 2020

Expiration: September 21, 2021

No longer available for credit.

Share

Faculty

Mark E. Robson

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Mark E. Robson, MD has disclosed that he has received consulting fees from Astra Zeneca and Pfizer.